Intrapleural Docetaxel Administration Using Medical Pleuroscopy in Malignant Effusion With Lung Cancer

Asan Medical Center4 enrolled

Overview

In this trial, the effect of intrapleural docetaxel administration using medical pleuroscopywill be evaluated in Lung Cancer patient with malignant effusion.

This study is designed to be pilot, single-center, open-label, single-arm, prospective, phase II trial of patient with NSCLC with pleurla effusion. Approximately 40 patients will be enrolled into the trial, and study will be performed to 31Dec2018 from IRB and Korea: MFDS approval date. Docetaxel will be administed to interpleural space using medical pleuroscopy in malignant effusion with lung cancer. Response evaluation will be done until confiramtion of disease progression.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Pleural Effusion, Malignant Non-small Cell Carcinoma

Interventions

intrapleural docetaxel administrationDRUG

intrapleural docetaxel administration using medical pleuroscopy in malignant effusion with lung cancer

Eligibility

Sex: ALLMin age: 20 YearsMax age: 79 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Age ≥ 20, and NSCLC patients with malignant pleural effusion and related symptoms * ECOG ≤ 2 * Blood test ANC≥ 1500/mm3, Hb ≥ 8.0g/dl, platelet count ≥ 100000/mm3 Serum creatinine ≤ 1.8mg/dl, Total bilirubin within normal limits, Transaminases ≤ 1.5 x UNL, Alkaline phosphatase ≤ 2.5 X UNL BUN ≤ 25mg/dl, Creatinine clearance ≥ 50ml/min * Negative serum or urine pregnancy test for women for childbearing age * Patients who provide written informed consent for the study Exclusion Criteria: * Age \< 20 * Patients who were previously perfomed pleurodesis * Patients who were previously treated with thoracic radiosurgery * Patinet with bilateral pleural effusion * Age ≥ 80yrs * Patients with histories of hypersensitivity to Docetaxel * Patients with cardiovascular, respiratory, hepatic, renal, gastrointestinal, neunological disease, asthma, MI, stroke, arrhythmia, uncontrolled hypertionsion, etc. that would effect absorption, distribution, and metabolism of IP or be risk factors during IP administrion. * Patients who could not understand the study procedure

Locations (1)

Asan Medical Center

Seoul, South Korea